{"id":40971,"date":"2025-09-09T13:18:40","date_gmt":"2025-09-09T05:18:40","guid":{"rendered":"https:\/\/flcube.com\/?p=40971"},"modified":"2025-09-09T13:18:40","modified_gmt":"2025-09-09T05:18:40","slug":"kintor-pharmaceutical-completes-kt%e2%80%91939-tyrosinase-inhibitor-safety-trial-highlights-cosmetic-potential","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40971","title":{"rendered":"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential"},"content":{"rendered":"\n<p>Kintor Pharmaceutical Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/9939:HKG\">HKG: 9939<\/a>) announced that it has finished enrolling <strong>130 subjects<\/strong> in the long\u2011term human safety study of <strong>KT\u2011939<\/strong>, an in\u2011house developed tyrosinase inhibitor designed to curb melanin production.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-trial-overview\">Trial Overview<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase:<\/strong> Long\u2011term safety (Phase\u202f1\/2)<\/li>\n\n\n\n<li><strong>Enrollment:<\/strong> 130 participants (\u226518\u202fyrs, Fitzpatrick skin types I\u2011V)<\/li>\n\n\n\n<li><strong>Duration:<\/strong> 12\u2011month follow\u2011up with quarterly safety assessments<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Incidence of treatment\u2011emergent adverse events (TEAEs)<\/li>\n\n\n\n<li><strong>Secondary Endpoints:<\/strong> Pharmacokinetics, skin\u2011pigmentation changes, and biomarker modulation<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-how-kt-939-works\">How KT\u2011939 Works<\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Targeted Inhibition<\/strong> \u2013 Specifically binds to the catalytic tyrosinase enzyme, blocking the oxidation of tyrosine.<\/li>\n\n\n\n<li><strong>Melanin Suppression<\/strong> \u2013 Reduces eumelanin synthesis, yielding lighter skin tone with minimal off\u2011target activity.<\/li>\n\n\n\n<li><strong>Dual Action<\/strong> \u2013 Exhibits antioxidant and anti\u2011inflammatory properties, mitigating oxidative stress associated with ultraviolet exposure.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-cosmetic-implications\">Cosmetic Implications<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy &amp; Safety<\/strong> \u2013 Early data suggest a strong safety profile with no serious adverse events reported.<\/li>\n\n\n\n<li><strong>Product Potential<\/strong> \u2013 Positions KT\u2011939 as a leading candidate for next\u2011generation depigmentation, anti\u2011aging, and photo\u2011protective formulations.<\/li>\n\n\n\n<li><strong>Regulatory Path<\/strong> \u2013 The safety profile supports forthcoming cosmetic regulatory filings in key markets (EU, US, APAC).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202f2 Efficacy Trial<\/strong> \u2013 Planned for early 2026, focusing on high\u2011pigmentation disorders (melasma, post\u2011inflammatory hyperpigmentation).<\/li>\n\n\n\n<li><strong>Commercial Partnerships<\/strong> \u2013 Kintor is open to strategic alliances with global dermo\u2011cosmetic brands for co\u2011development and licensing.<\/li>\n\n\n\n<li><strong>Manufacturing Scale\u2011Up<\/strong> \u2013 Production capacity is being expanded to meet anticipated demand should the compound reach market approval.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h4>\n\n\n\n<p>The global anti\u2011pigmentation market is projected to exceed <strong>USD\u202f5\u202fbn<\/strong> by 2030, driven by rising consumer demand for skin\u2011lightening and anti\u2011aging products. KT\u2011939\u2019s selective mechanism and favorable safety profile could offer a competitive edge over current non\u2011selective agents such as hydroquinone and kojic acid.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025090900010_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025090900010_c.\"><\/object><a id=\"wp-block-file--media-9ba069bd-263d-49b0-b314-4b4c3ce58906\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025090900010_c.pdf\">2025090900010_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025090900010_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9ba069bd-263d-49b0-b314-4b4c3ce58906\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Kintor Pharmaceutical Limited (HKG: 9939) announced that it has finished enrolling 130 subjects in the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40974,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,958,547,100],"class_list":["post-40971","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-9939","tag-kintor-pharmaceutical","tag-medical-aesthetics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kintor Pharmaceutical Limited (HKG: 9939) announced that it has finished enrolling 130 subjects in the long\u2011term human safety study of KT\u2011939, an in\u2011house developed tyrosinase inhibitor designed to curb melanin production.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40971\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential\" \/>\n<meta property=\"og:description\" content=\"Kintor Pharmaceutical Limited (HKG: 9939) announced that it has finished enrolling 130 subjects in the long\u2011term human safety study of KT\u2011939, an in\u2011house developed tyrosinase inhibitor designed to curb melanin production.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40971\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-09T05:18:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0904.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential\",\"datePublished\":\"2025-09-09T05:18:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971\"},\"wordCount\":290,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0904.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 9939\",\"Kintor Pharmaceutical\",\"Medical aesthetics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40971#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40971\",\"name\":\"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0904.webp\",\"datePublished\":\"2025-09-09T05:18:40+00:00\",\"description\":\"Kintor Pharmaceutical Limited (HKG: 9939) announced that it has finished enrolling 130 subjects in the long\u2011term human safety study of KT\u2011939, an in\u2011house developed tyrosinase inhibitor designed to curb melanin production.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40971\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0904.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0904.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40971#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential - Insight, China&#039;s Pharmaceutical Industry","description":"Kintor Pharmaceutical Limited (HKG: 9939) announced that it has finished enrolling 130 subjects in the long\u2011term human safety study of KT\u2011939, an in\u2011house developed tyrosinase inhibitor designed to curb melanin production.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40971","og_locale":"en_US","og_type":"article","og_title":"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential","og_description":"Kintor Pharmaceutical Limited (HKG: 9939) announced that it has finished enrolling 130 subjects in the long\u2011term human safety study of KT\u2011939, an in\u2011house developed tyrosinase inhibitor designed to curb melanin production.","og_url":"https:\/\/flcube.com\/?p=40971","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-09T05:18:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0904.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40971#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40971"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential","datePublished":"2025-09-09T05:18:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40971"},"wordCount":290,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40971#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0904.webp","keywords":["Clinical trial approval \/ initiation","HKG: 9939","Kintor Pharmaceutical","Medical aesthetics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40971#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40971","url":"https:\/\/flcube.com\/?p=40971","name":"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40971#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40971#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0904.webp","datePublished":"2025-09-09T05:18:40+00:00","description":"Kintor Pharmaceutical Limited (HKG: 9939) announced that it has finished enrolling 130 subjects in the long\u2011term human safety study of KT\u2011939, an in\u2011house developed tyrosinase inhibitor designed to curb melanin production.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40971#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40971"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40971#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0904.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0904.webp","width":1080,"height":608,"caption":"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40971#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kintor Pharmaceutical Completes KT\u2011939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0904.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40971"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40971\/revisions"}],"predecessor-version":[{"id":40975,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40971\/revisions\/40975"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40974"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}